<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193284</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI HN 04</org_study_id>
    <secondary_id>IRUSIRES0047</secondary_id>
    <secondary_id>IIT 15038</secondary_id>
    <nct_id>NCT00193284</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer</brief_title>
  <official_title>A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <brief_summary>
    <textblock>
      Although gefitinib has been combined successfully with various chemotherapeutic regimens with&#xD;
      minimal increase in overall toxicity, experience with concurrent radiation therapy is&#xD;
      limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel&#xD;
      combination of chemotherapy, radiation therapy, and gefitinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, patients will receive:&#xD;
&#xD;
      Induction Therapy&#xD;
&#xD;
        -  Docetaxel&#xD;
&#xD;
        -  Carboplatin&#xD;
&#xD;
        -  5-FU&#xD;
&#xD;
        -  Gefitinib&#xD;
&#xD;
      Combined Modality Therapy&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
        -  Radiation therapy&#xD;
&#xD;
        -  Gefitinib&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
        -  Radiation therapy&#xD;
&#xD;
        -  Gefitinib&#xD;
&#xD;
        -  Docetaxel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in this study, you must meet the following criteria:&#xD;
&#xD;
          -  Squamous carcinoma of the head and neck.&#xD;
&#xD;
          -  Primary tumor nasopharynx, oral cavity, oropharynx, hypopharynx, and larynx&#xD;
&#xD;
          -  Squamous carcinoma in cervical nodes no identified primary site&#xD;
&#xD;
          -  Must be considered to have low cure rates with local therapy&#xD;
&#xD;
          -  Previously untreated with chemotherapy or radiation therapy.&#xD;
&#xD;
          -  Able to perform activities of daily living without assistance&#xD;
&#xD;
          -  Adequate bone marrow, liver, and kidney function&#xD;
&#xD;
          -  Mild peripheral neuropathy is allowed&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Voluntarily give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        You cannot participate in this study if any of the following apply to you:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  History of prior malignancy within the last five years&#xD;
&#xD;
          -  Severe or uncontrolled systemic disease&#xD;
&#xD;
          -  Significant clinical disorder or laboratory finding&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Active interstitial lung disease&#xD;
&#xD;
        Please note: There are additional inclusion/exclusion criteria. The study center will&#xD;
        determine if you meet all of the criteria. If you do not qualify for the trial, study&#xD;
        personnel will explain the reasons. If you do qualify, study personnel will explain the&#xD;
        trial in detail and answer any questions you may have.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Hainsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hainsworth JD, Spigel DR, Burris HA 3rd, Markus TM, Shipley D, Kuzur M, Lunin S, Greco FA. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer. 2009 May 15;115(10):2138-46. doi: 10.1002/cncr.24265.</citation>
    <PMID>19288572</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>June 18, 2010</last_update_submitted>
  <last_update_submitted_qc>June 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

